Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2012OncoImmunologyOpen Access

PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

KKKatarzyna KarwaczBrigham and Women's HospitalFAFrederick ArceUniversity College LondonCBChristopher BricogneUniversity of Oxford

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Karwacz et al. (2012) studied this question.

synapsesocial.com/papers/6a6f778635aa2c282ce0d58dhttps://doi.org/10.4161/onci.1.1.17824
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting dendritic cell signaling to regulate the response to immunization2008 · 120 citations
  2. 2Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells2009 · 503 citations
  3. 3Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation2000 · 5,352 citations
  4. 4PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8+ T cells2011 · 274 citations
  5. 5PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells2004 · 646 citations